Vol.

No.

July 03, 2025Jul 03, 2025

DOWNLOAD THE PDF

She flew Black Hawks and battled cancer—now Col. Susan Fondy grapples with cuts to lymphedema research

Cover Story

Clinical

She flew Black Hawks and battled cancer—now Col. Susan Fondy grapples with cuts to lymphedema research

By Jacquelyn Cobb

Don’t try to convince Col. Susan Fondy that lymphedema doesn’t merit interest from medical researchers.

Free Guest Editorial

As cancer scientists, we must change how we engage with the public on the impact of NIH cuts
What the scientific method obscures

By George J. Weiner and Elizabeth M. Jaffee

Free

In weekly vigils, current and former NIH staff grieve the impact of Trump cuts
The Saturday gatherings at NIH’s Metro station are part graveside service, part street theater

By Claire Marie Porter

Scaling excellence: How City of Hope is transforming cancer care delivery

By Alan H. Bryce and Walter M. Stadler

Free In the Archives

Since 1991, the Women’s Health Initiative has saved lives, cut costs, and fostered team science

Podcasts

In The Headlines: George Weiner on the importance of patients’ stories

Cancer Policy

Congress passes Trump’s megabill featuring historically steep Medicaid cuts

Publications based on NIH-funded science must be made free immediately, HHS decrees

NIDA director Volkow gets candid on addiction in Bhattacharya’s podcast

In Brief

Neil Iyengar joins Winship as survivorship director, co-director of Breast Oncology Program

Besim Ogretmen named assistant vice president for research at MUSC

Florida Cancer Specialists & Research Institute awarded $3.3 million in grants to advance cancer care in Florida

Hebrew University, Lombardi establish research collaboration

UCLA’s Roger Lo awarded $1 million to help prevent cancer relapse

Clinical Roundup

More than half of cancer centers see AI as answer to operational challenges, report shows

Scientists uncover new approach for targeting aggressive breast cancer

Study findings expand donor pool for blood cancers

Rare pancreatic cancer shows strong response to immunotherapy

Scientists wipe out aggressive brain cancer tumors by targeting cellular “motors”

Drugs & Targets

FDA grants accelerated approval to Zegfrovy for NSCLC with EGFR exon20ins

FDA grants accelerated approval to linvoseltamab-gcpt for r/r MM

REMS for currently approved BCMA- and CD19-directed autologous CAR T-cell immunotherapies eliminated

NCI Trials

NCI Trials for July 2025

The National Cancer Institute approved the following clinical research studies last month.

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 52 | Issue 08 - February 27, 2026